245 related articles for article (PubMed ID: 20562910)
21. PICH promotes sister chromatid disjunction and co-operates with topoisomerase II in mitosis.
Nielsen CF; Huttner D; Bizard AH; Hirano S; Li TN; Palmai-Pallag T; Bjerregaard VA; Liu Y; Nigg EA; Wang LH; Hickson ID
Nat Commun; 2015 Dec; 6():8962. PubMed ID: 26643143
[TBL] [Abstract][Full Text] [Related]
22. Mitotic bypass via an occult cell cycle phase following DNA topoisomerase II inhibition in p53 functional human tumor cells.
Smith PJ; Marquez N; Wiltshire M; Chappell S; Njoh K; Campbell L; Khan IA; Silvestre O; Errington RJ
Cell Cycle; 2007 Aug; 6(16):2071-81. PubMed ID: 17721081
[TBL] [Abstract][Full Text] [Related]
23. Chromosomes with two intact axial cores are induced by G2 checkpoint override: evidence that DNA decatenation is not required to template the chromosome structure.
Andreassen PR; Lacroix FB; Margolis RL
J Cell Biol; 1997 Jan; 136(1):29-43. PubMed ID: 9008701
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase IIα in chromosome instability and personalized cancer therapy.
Chen T; Sun Y; Ji P; Kopetz S; Zhang W
Oncogene; 2015 Jul; 34(31):4019-31. PubMed ID: 25328138
[TBL] [Abstract][Full Text] [Related]
25. Sister chromatid decatenation: bridging the gaps in our knowledge.
Broderick R; Niedzwiedz W
Cell Cycle; 2015; 14(19):3040-4. PubMed ID: 26266709
[TBL] [Abstract][Full Text] [Related]
26. The α isoform of topoisomerase II is required for hypercompaction of mitotic chromosomes in human cells.
Farr CJ; Antoniou-Kourounioti M; Mimmack ML; Volkov A; Porter AC
Nucleic Acids Res; 2014 Apr; 42(7):4414-26. PubMed ID: 24476913
[TBL] [Abstract][Full Text] [Related]
27. Rad9A is required for G2 decatenation checkpoint and to prevent endoreduplication in response to topoisomerase II inhibition.
Greer Card DA; Sierant ML; Davey S
J Biol Chem; 2010 May; 285(20):15653-15661. PubMed ID: 20305300
[TBL] [Abstract][Full Text] [Related]
28. SUMOylation of the C-terminal domain of DNA topoisomerase IIα regulates the centromeric localization of Claspin.
Ryu H; Yoshida MM; Sridharan V; Kumagai A; Dunphy WG; Dasso M; Azuma Y
Cell Cycle; 2015; 14(17):2777-84. PubMed ID: 26131587
[TBL] [Abstract][Full Text] [Related]
29. TopoIIα prevents telomere fragility and formation of ultra thin DNA bridges during mitosis through TRF1-dependent binding to telomeres.
d'Alcontres MS; Palacios JA; Mejias D; Blasco MA
Cell Cycle; 2014; 13(9):1463-81. PubMed ID: 24626180
[TBL] [Abstract][Full Text] [Related]
30. PIASy-dependent SUMOylation regulates DNA topoisomerase IIalpha activity.
Ryu H; Furuta M; Kirkpatrick D; Gygi SP; Azuma Y
J Cell Biol; 2010 Nov; 191(4):783-94. PubMed ID: 21079245
[TBL] [Abstract][Full Text] [Related]
31. Small molecule modulation of the human chromatid decatenation checkpoint.
Haggarty SJ; Koeller KM; Kau TR; Silver PA; Roberge M; Schreiber SL
Chem Biol; 2003 Dec; 10(12):1267-79. PubMed ID: 14700634
[TBL] [Abstract][Full Text] [Related]
32. Mitotic entry upon Topo II catalytic inhibition is controlled by Chk1 and Plk1.
Arroyo M; Cañuelo A; Calahorra J; Hastert FD; Sánchez A; Clarke DJ; Marchal JA
FEBS J; 2020 Nov; 287(22):4933-4951. PubMed ID: 32144855
[TBL] [Abstract][Full Text] [Related]
33. Metnase mediates chromosome decatenation in acute leukemia cells.
Wray J; Williamson EA; Sheema S; Lee SH; Libby E; Willman CL; Nickoloff JA; Hromas R
Blood; 2009 Aug; 114(9):1852-8. PubMed ID: 19458360
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Guo L; Liu X; Nishikawa K; Plunkett W
Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase IIalpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure.
Soubeyrand S; Pope L; Haché RJ
Mol Oncol; 2010 Feb; 4(1):38-51. PubMed ID: 19858003
[TBL] [Abstract][Full Text] [Related]
36. Hypersensitivity of Ku-deficient cells toward the DNA topoisomerase II inhibitor ICRF-193 suggests a novel role for Ku antigen during the G2 and M phases of the cell cycle.
Muñoz P; Zdzienicka MZ; Blanchard JM; Piette J
Mol Cell Biol; 1998 Oct; 18(10):5797-808. PubMed ID: 9742097
[TBL] [Abstract][Full Text] [Related]
37. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/.
Downes CS; Clarke DJ; Mullinger AM; Giménez-Abián JF; Creighton AM; Johnson RT
Nature; 1994 Dec; 372(6505):467-70. PubMed ID: 7984241
[TBL] [Abstract][Full Text] [Related]
38. The G2-phase decatenation checkpoint is defective in Werner syndrome cells.
Franchitto A; Oshima J; Pichierri P
Cancer Res; 2003 Jun; 63(12):3289-95. PubMed ID: 12810661
[TBL] [Abstract][Full Text] [Related]
39. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells.
Wray J; Williamson EA; Royce M; Shaheen M; Beck BD; Lee SH; Nickoloff JA; Hromas R
PLoS One; 2009; 4(4):e5323. PubMed ID: 19390626
[TBL] [Abstract][Full Text] [Related]
40. PTEN stabilizes TOP2A and regulates the DNA decatenation.
Kang X; Song C; Du X; Zhang C; Liu Y; Liang L; He J; Lamb K; Shen WH; Yin Y
Sci Rep; 2015 Dec; 5():17873. PubMed ID: 26657567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
